Skip to main content
Premium Trial:

Request an Annual Quote

Arrays: Going Like Hotcakes

Today's Wall Street Journal includes an article ($) looking into the growing price war between Affymetrix and Illumina. Citing the value of the current array market as somewhere between $200 million and $350 million with projected growth rates of 25 percent to 40 percent, the WSJ says that as a result of "a big misstep last year," Affy has essentially "handed the hottest part of the market to its nimble young rival, Illumina."

That misstep -- the release of what WSJ calls an "under-tested" 500K SNP chip -- eventually forced Affy to slash prices in an effort to win back the marketshare gained by Illumina in the interim. Sales are already up, and the end result of the skirmish might actually be increased use of arrays on all fronts.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.